transcriptional activity . >https://pharma. lonza. com/offerings/specialized-capabilities/expressions-technologies/GS-piggyBac >
Innovent Bio announced that its anti-CTLA-4 monoclonal antibody IBI310 has been included
Time of Update: 2022-05-20
. Advanced cervical cancer The existing treatment methods for patients are very limited, chemotherapy and other treatments are ineffective, the overall survival rate of patients is only a few months, and new
The 9th domestic Yuheng Pharmaceutical LAG3 monoclonal antibody was approved for clinical use
Time of Update: 2022-05-18
Article source: Medical Cube InfoAuthor: sunshineOn April 19, the CDE official website showed that Yuheng Pharmaceutical's recombinant fully human anti-LAG-3 monoclonal antibody injection was approved for clinical use in the treatment of advanced malignant tumors .
" neutralizing antibody 35B5 neutralizes the Omicron strain and its mechanism
Time of Update: 2022-05-18
Since its discovery in November last year, the SARS-CoV-2 superstrain Omicron has rapidly spread globally and has gradually replaced the previous Variants of Concern (VOCs) that were identified
AACR 2022: NK Cells and Bispecific Antibody AFM13 Complexes Consistently Induce Lymphoma Remission
Time of Update: 2022-05-18
>Original source:>Original source:https://firstwordpharma. com/story/5545475>https
AstraZeneca's new crown antibody cocktail therapy can provide protection for at least 6 months in high-risk groups
Time of Update: 2022-05-17
AstraZeneca said today that its long-acting antibody cocktail, Evusheld (tixagevimab and cilgavimab), compared with placebo in a late-stage pre-exposure prophylaxis trial, reduced patients with symptomatic COVID-19 infection six months later.
FDA extends review of COVID-19 antibody cocktail REGEN-COV as pre-exposure prophylaxis
Time of Update: 2022-05-16
However, the FDA restricted the use of certain antibody treatments, including REGEN-COV, earlier this year after data suggested they were unlikely to be effective against the Omicron variants .
EBioMedicine: Novel coronavirus mRNA vaccine induces higher antibody affinity and IgG titers
Time of Update: 2022-05-16
) of polyclonal antibodies to 2019-nCoV RBD protein for post-first (Vx-1; a) or post-secondary vaccination (Vx-2; b) Peak titers per vaccination (day 14) in plasma samples of non-postpartum controls (n = 13 black) or postpartum women (n = 13 red) were
Phase 3 clinical trial: second-generation new crown vaccine produces high levels of neutralizing antibodies
Time of Update: 2022-05-15
The novel coronavirus infection (COVID-19 virus) vaccine developed by the University of Washington School of Medicine has been shown to be safe and effective in late-stage clinical trials .
Acta Haematol: Unique mechanism of IgM antibody-mediated acquired von Willebrand syndrome
Time of Update: 2022-05-15
There were no reports of bleeding in the patient's past or family history, and laboratory tests showed decreased VWF antigen and VWF activity .
BeiGene's CD3/CD19 Dual Antibody Belintoumumab New Indication Approved
Time of Update: 2022-05-14
Article source: Medical Cube Info>Author: info>On April 29, BeiGene's new indication of belintoumumab for injection submitted
TNF-α antibody drug market competition is becoming more and more intense, and product price reduction has become a trend
Time of Update: 2022-05-10
In the domestic market, in recent years, with the continuous entry of infliximab and adalimumab biosimilar companies, the TNF-α antibody drug market has become more competitive, and product price reductions have become a trend .
Severe obesity impairs antibody response to COVID-19 vaccine, study shows
Time of Update: 2022-05-08
/> The research was conducted by Professor Volkan Demirhan Yumuk and colleagues at Istanbul University, Turkey . >The study also found that people with severe obesity
Three inspirations from the CDE double antibody R&D guidelines for the industry
Time of Update: 2022-05-08
>At present, there are 11 double-antibody products in the phase III clinical/marketing application stage in the world, 4 of which are independently developed by China, and 2 of which are owned by Aesco, including Cardonili (PD-1/CTLA-4, which has been
BeiGene's Bispecific Antibody Therapy Approved in China to Treat Certain Childhood Leukemia
Time of Update: 2022-05-08
A few days ago, BeiGene announced that the National Medical Products Administration (NMPA) of China has approved Belito (Belintoumumab for injection, English trade name Blincyto
